Patent ID: 8900553

Claim:
A waterless foamable pharmaceutical composition, comprising a foamable carrier and at least one liquefied or compressed gas propellant, wherein the foamable carrier comprises: a) about 60% to about 95% by weight of the foamable carrier of at least one liquid oil selected from the group comprising a mineral oil, a MCT oil, a liquid paraffin, a vegetable oil, an essential oil, an organic oil, a lipid, or a mixture of two or more thereof comprising about 60-90% mineral oil; b) about 0.5% to about 15% by weight of the foamable carrier of a silicone; and c) about 0.01% to about 25% by weight of the foamable carrier of at least one foam stabilizing agent comprising glyceryl monostearate; wherein the foamable carrier is a single phase; wherein the foam stabilizing agent optionally comprises at least one foam adjuvant; wherein the silicone is selected from the group consisting of a siloxane compound having 4-6 Si—O groups in its backbone, a cyclomethicone, a cyclotetrasiloxane, a cyclopentasiloxane, a cyclohexasiloxane, a phenyl trimethicone, a stearyl dimethicone, a cetyl dimethicone, a caprylyl methicone, a PEG/PPG 18/18 dimethicone, a dimethiconol, and a mixture of any two or more thereof; wherein the composition is essentially free of water; wherein the ratio of the foamable carrier to the propellant is 100:3 to 100:35; wherein the resultant foam does not collapse immediately upon release and is breakable on mechanical shear; wherein the waterless foamable pharmaceutical composition comprises a minocycline or a doxycycline or both; and wherein the minocycline or the doxycycline is stable for at least 3 weeks at 25° C. in the waterless foamable pharmaceutical composition.